herceptin -bound gold nanoshells seem to work BOTH vs herceptin-sensitive&resistant

[Lani]

breast cancer via near-infrared photothermal ablation (wavelength of light used to heat up ONLY the cancer cells, leaving the others untouched)

I have been reporting here on the work done at Rice since May 2005--it is moving right along, just not fast enough!

Breast Cancer Res Treat. 2010 Mar 10. [Epub ahead of print]
Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells.
Carpin LB, Bickford LR, Agollah G, Yu TK, Schiff R, Li Y, Drezek RA.

Department of Bioengineering, Rice University, 6100 Main St., MS-142, Houston, TX, 77005, USA.
Trastuzumab is a FDA-approved drug that has shown clinical efficacy against HER2+ breast cancers and is commonly used in combination with other chemotherapeutics. However, many patients are innately resistant to trastuzumab, or will develop resistance during treatment. Alternative treatments are needed for trastuzumab-resistant patients. Here, we investigate gold nanoparticle-mediated photothermal therapies as a potential alternative treatment for chemotherapy-resistant cancers. Gold nanoshell photothermal therapy destroys the tumor cells using heat, a physical mechanism, which is able to overcome the cellular adaptations that bestow trastuzumab resistance. By adding anti-HER2 to the gold surface of the nanoshells as a targeting modality, we increase the specificity of the nanoshells for HER2+ breast cancer. Silica-gold nanoshells conjugated with anti-HER2 were incubated with both trastuzumab-sensitive and trastuzumab-resistant breast cancer cells. Nanoshell binding was confirmed using two-photon laser scanning microscopy, and the cells were then ablated using a near-infrared laser. We demonstrate the successful targeting and ablation of trastuzumab-resistant cells using anti-HER2-conjugated silica-gold nanoshells and a near-infrared laser. This study suggests potential for applying gold nanoshell-mediated therapy to trastuzumab-resistant breast cancers in vivo.

PMID: 20217215